Advaxis: Up on positive trial data from combination therapy for lung cancer

Ayala Pharmaceuticals

14/05/2020 13:58

** Shares of biotech co  ADXS.O  rise 10.70% to 77 cents
premarket
    ** Co reports positive data from ongoing study of its drug
ADXS-503 in patients with non-small cell lung cancer, or NSCLC
 urn:newsml:reuters.com:*:nGNX81tSLJ
    ** The trial studied ADXS-503, both on its own and in
combination with Merck's  MRK.N  anti-cancer drug Keytruda - co
    ** Co says study found patients who took the combination of
drugs showed sustained benefit, and the drug appeared safe and
well-tolerated
    ** ADXS to expand study of the combination treatment and
also start another part of the trial to evaluate the therapy for
NSCLC patients who cannot tolerate Keytruda with chemotherapy,
the current standard of care regimen 
    ** Non-small cell lung cancer accounts for a majority of all
lung cancer cases in the United States
    ** Up to last close, ADXS down 18.90% YTD
    

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))